T. Rowe Price Investment Management, Inc. Crinetics Pharmaceuticals, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $166 Billion
- Q3 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 1,068,532 shares of CRNX stock, worth $61.3 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
1,068,532
Previous 1,347,210
20.69%
Holding current value
$61.3 Million
Previous $60.3 Million
9.51%
% of portfolio
0.03%
Previous 0.04%
Shares
7 transactions
Others Institutions Holding CRNX
# of Institutions
242Shares Held
79.6MCall Options Held
23.3KPut Options Held
44.3K-
Vanguard Group Inc Valley Forge, PA6.29MShares$361 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$358 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL5.89MShares$338 Million2.95% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.94MShares$284 Million0.03% of portfolio
-
Wellington Management Group LLP Boston, MA4.46MShares$256 Million0.04% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $3.08B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...